The new peritoneal dialysis solutions: friends only, or foes in part?
- 1 November 2007
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 3 (11) , 604-612
Abstract
Over the past decade new solutions for peritoneal dialysis have been developed in an effort to reduce the bioincompatibility of conventional glucose-containing, lactate-buffered solutions, and thereby to improve the clinical outcomes of peritoneal dialysis. The new solutions contain either other non-glucose osmotic agents, such as glucose polymers or amino acids, or have a neutral pH; the buffer content is altered in some of the new solutions. In vitro and in vivo studies have shown the biocompatibility of these new solutions to be superior to that of standard solutions. In this paper, available clinical data on the use of these new solutions are reviewed. In general, the data indicate improved biocompatibility of the new solutions; a number of studies, however, detected no superiority when levels of accepted markers of biocompatibility, such as vascular endothelial growth factor or hyaluronic acid, were measured. This finding could be explained by the assumption that the new peritoneal dialysis solutions not only induce less damage to the peritoneal membrane but also better maintain repair mechanisms, which apparently are associated with enhanced release of such markers.Keywords
This publication has 89 references indexed in Scilit:
- The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluidsNephrology Dialysis Transplantation, 2007
- Icodextrine and Insulin Resistance in Continuous Ambulatory Peritoneal Dialysis PatientsRenal Failure, 2007
- Peritoneal Dialysis with Solutions Containing Amino Acids Plus Glucose Promotes Protein Synthesis during Oral FeedingClinical Journal of the American Society of Nephrology, 2007
- The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patientsClinical Nephrology, 2006
- Dialysate as FoodJournal of the American Society of Nephrology, 2005
- Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescriptionKidney International, 2005
- Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patientsClinical Nephrology, 2002
- Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation productsKidney International, 2001
- Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearanceNephrology Dialysis Transplantation, 1997
- In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysisNephrology Dialysis Transplantation, 1997